CRB Monitor Securities Database Updates
During the week of June 10 - 16, 2024, CRB Monitor’s research team made several updates to securities’ information and added source documents & relevant news articles to the CRB Monitor database.
Summary of the updates for the Week of June 10 - 16, 2024:
|
Tier |
Total # |
Active / Inactive / Pre-IPO |
Added |
Removed |
Net Change |
|
Tier 1A |
146 |
121 / 23 / 2 |
+0 | -0 | +0 |
|
Tier 1B |
706 |
555 / 149 / 2 |
+0 | -0 | +0 |
|
Tier 2 |
316 |
296 / 15 / 5 |
+0 | -1 | -1 |
|
Tier 3 |
482 |
454 / 27 / 1 |
+0 | -0 | +0 |
|
Total Issuances |
1,650 |
1,426 / 214 / 10 |
+0 | -1 | -1 |
|
Total Issuers (w/o Pre-IPOs) |
1,240 |
- |
+0 | -1 | -1 |
|
Total Issuers (w/ Pre-IPOs) |
1,250 |
- |
+0 | -1 | -1 |
Removed 1 Tier 2 Security:
- -1 = Discarded Business Record from Database: (“BioHarvest Sciences Inc.”)
- Rationale = BioHarvest Sciences Inc. is a Canada-based biotechnology company focusing on botanical synthesis to develop therapeutic solutions including nutraceutical health/wellness products and dietary supplements. BioHarvest Solutions was previously involved in research to adapt its platform technology to be used in the pharmaceutical cannabis industry to produce cannabis cells. However, per its own admission: “with the new focus on the creation and accelerated building of the services business unit, the company has decided to permanently discontinue any activity related to its own development of medicinal cannabis.” The company previously “indefinitely ‘put on hold’ its cannabis and hemp commercialization.” There is no evidence to suggest that this company has any other connection to or is actively engaged in the cannabis industry. As a result, this business no longer qualifies for inclusion.
- Rationale = BioHarvest Sciences Inc. is a Canada-based biotechnology company focusing on botanical synthesis to develop therapeutic solutions including nutraceutical health/wellness products and dietary supplements. BioHarvest Solutions was previously involved in research to adapt its platform technology to be used in the pharmaceutical cannabis industry to produce cannabis cells. However, per its own admission: “with the new focus on the creation and accelerated building of the services business unit, the company has decided to permanently discontinue any activity related to its own development of medicinal cannabis.” The company previously “indefinitely ‘put on hold’ its cannabis and hemp commercialization.” There is no evidence to suggest that this company has any other connection to or is actively engaged in the cannabis industry. As a result, this business no longer qualifies for inclusion.
All newly-identified CRBs during the week:
|
Company Name |
Tier |
Pure-Play | Sector |
Description |
| N/A | N/A | N/A | N/A | N/A |